endpts.com·Jul 10, 2026
German lawmakers have passed a cost-saving healthcare bill that drug manufacturers argue could negatively impact their operations in the country, leading to significant criticism from the pharmaceutical industry.
The newly passed cost-saving bill by German lawmakers, aimed at reducing domestic healthcare spending, poses significant challenges for pharmaceutical companies operating in the region. This legislative change could potentially drive drugmakers out of the market, signaling a need for healthtech and biotech firms to reassess their European market strategies and explore opportunities in markets with more favorable regulatory environments.